Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709763 | 0.85 | PDE10A (0.62) | PDE10A | |
| SCHEMBL2630936 | 0.82 | PDE10A (0.71) | PDE10A | |
| SCHEMBL7706988 | 0.80 | PDE10A (0.61) | PDE10A | |
| SCHEMBL7712099 | 0.80 | PDE10A (0.51) | PDE10A | |
| SCHEMBL2593687 | 0.80 | PDE10A (0.71) | PDE10A | |
| SCHEMBL7710220 | 0.79 | PDE10A (0.67) | PDE10A | |
| SCHEMBL15134923 | 0.79 | PDE10A (0.67) | PDE10A | |
| SCHEMBL7710223 | 0.79 | PDE10A (0.67) | PDE10A | |
| SCHEMBL2631082 | 0.78 | PDE10A (0.60) | PDE10A | |
| SCHEMBL2631171 | 0.77 | PDE10A (1.00) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376450-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497265-B2 | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2011143495-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253186-A1 | HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE7A | PDE10A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.